SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study

PASS study to evalaute the risks of MDS/AML and secondary primary malignancies in adult patients with platinum-sensitive, relapsed, high grade serous epithelial ovarian, fallopian tube,or primary peritoneal cancer receiving maintenance treatment with Zejula